Garry E. Menzel, President and CEO at TCR2 THERAPEUTICS INC. (TCRR), sold 18,425 shares at $1.25 ($23K) on 2022-12-08, disclosed to the SEC on 2022-12-09.
Scheduled sale ($23k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.28 | 9,111 | $12K | 50.0% |
| 2 | $1.25 | 9,314 | $12K | 50.0% |
| Total | $1.26 avg | 18,425 | $23K | 100% |
| Filing → |
| TCRR | SELL | 2022-12-07 | $32K | — | Filing → |
| TCRR | SELL | 2022-12-05 | $12K | — | Filing → |